Featured Blog Posts – May 2014 Archive (3)
Staff Congressional Committee That Funds the FDA Recognizes PPMD-Led Efforts on Benefit/Risk, Draft Guidance; Applauds Collaboration with Agency
For the first time ever, the appropriations bill that funds the Food and Drug Administration includes report language focused on Duchenne muscular dystrophy and championed by PPMD advocates.
This week the House Appropriations Committee approved the Fiscal Year 2015 Department of Agriculture and FDA spending bill, clearing the way for the full House to act on…
ContinueAdded by Pat Furlong on May 30, 2014 at 11:22am — No Comments
Staff A Good Day for Duchenne
EMA grants Conditional Approval for Ataluren
Ataluren, PTC Therapeutics’ nonsense suppression drug received Conditional Approval. This is a big moment for Duchenne, a…
Added by Pat Furlong on May 23, 2014 at 9:30am — 6 Comments
Staff PPMD Congressional Champions Voice the Need for Action on the MD-CARE Act
On May 20th, the House Energy and Commerce Subcommittee on Health held a hearing entitled, 21st Century Cures: The President’s Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation.
The hearing was led by Chairman Joe Pitts (R-PA) and is part of the new 21st Century Cures initiative that seeks to accelerate the discovery, development and delivery of promising new treatments to patients.…
ContinueAdded by Ryan Fischer on May 22, 2014 at 3:30pm — No Comments
Latest Featured Blog Posts
- PPMD Designates UC Davis a Certified Duchenne Care Center
- PPMD Working with FDA to Plan Landmark Pediatric Advisory Committee Meeting to Improve Clinical Trial Experience
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 3: Clinical Trial Readiness from the Viewpoint of Clinicians and Infrastructure
- ACTION ALERT: Make Your Voice Heard on New Healthcare Proposal
- PPMD's Duchenne Drug Development Roundtable Meeting Series, Part 2: Optimizing Clinical Trials
- PPMD Designates Ann & Robert H. Lurie Children's Hospital of Chicago a Certified Duchenne Care Center
- Marathon Pharmaceuticals Pauses Commercialization of EMFLAZA™ (deflazacort)
Most Popular Featured Blog Posts
- FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy
- Deflazacort Approved in the U.S. for Duchenne
- A Historic Day for Duchenne
- Early morning calls
- Action ALERT: Urge Congress to Vote YES on 21st Century Cures Act
- PPMD Announces Gene Therapy Forum
- What You Need to Know about Duchenne & Viral Gastroenteritis (That Horrible Stomach Bug!)
Featured Monthly Archives
2017
2016
- December (1)
- November (1)
- October (3)
- September (2)
- August (2)
- July (2)
- June (1)
- May (2)
- April (2)
- March (6)
- February (4)
- January (3)
2015
- December (3)
- November (3)
- October (4)
- September (5)
- August (5)
- July (6)
- June (3)
- May (2)
- April (4)
- March (3)
- February (5)
- January (7)
2014
- December (2)
- November (3)
- October (5)
- September (3)
- August (1)
- July (2)
- June (1)
- May (3)
- April (3)
- March (1)
- February (1)
- January (1)
2013
- December (5)
- November (4)
- October (6)
- September (5)
- August (3)
- July (5)
- June (3)
- May (6)
- April (3)
- March (6)
- February (7)
- January (2)
2012
- December (3)
- November (5)
- October (12)
- September (11)
- August (8)
- July (4)
- June (5)
- May (5)
- April (5)
- March (8)
- February (6)
- January (5)
2011
- December (5)
- November (11)
- October (9)
- September (6)
- August (3)
- July (1)
- June (3)
- May (2)
- April (6)
- March (3)
- February (4)
- January (4)
2010
- December (4)
- November (2)
- October (2)
- September (4)
- August (3)
- July (3)
- June (3)
- May (3)
- April (4)
- February (1)
- January (6)
2009
- December (5)
- November (7)
- October (1)
- September (3)
- August (5)
- July (2)
- May (2)
- April (2)
- March (4)
- February (3)
- January (1)
2008
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
